Simone Morea
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
Simone Morea has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Carlo Messina
Ospedale Arnas Civico, Clinical Oncology, Palermo, Italy
1 shared publication - Daniele Di Biagio
Centro di Medicina Nucleare, Ospedale San Pietro Fatebenefratelli, 00189 Rome, Italy
1 shared publication - Pierpaolo Alongi
Department of Biomedicine, Neuroscience and Advanced Diagnostics (BIND), University of Palermo, 90127 Palermo, Italy
1 shared publication - Roberto Cannella
Department of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, Palermo, Italy
1 shared publication - Rosa Alba Pugliesi
Section of Radiology, Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND), University of Palermo, Via del Vespro 129, 90127 Palermo, Italy
1 shared publication
Latest Publications
- Open Access
- 31 December 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (1) , 311
The Rise of Total-Body PET/CT: Advancing Molecular Imaging Toward Early Cancer Detection and Potential Future Application in Prevention Healthcare
Positron Emission Tomography (PET) is undergoing a profound transformation. Driven by the convergence of highly sensitive long-axial field-of-view (LAFOV) total-body PET systems and an expanding portfolio of targeted radiopharmaceuticals, PET is progressively evolving beyond its traditional role in oncologic diagnosis and staging. Ultra-sensitive scanners enable whole-body imaging with markedly reduced radiotracer doses, rapid acquisition times, and true dynamic multiparametric imaging across all organs simultaneously. In parallel, molecularly targeted radioligands support tumour phenotyping, theranostic applications, and personalized dosimetry. Together, these advances position PET as a systemic imaging platform capable of interrogating whole-body tumour biology, guiding precision therapies, and potentially enabling early detection or surveillance strategies in selected high-risk populations. This narrative review summarizes the technological foundations of total-body PET, reviews current clinical and translational applications, discusses opportunities and limitations for early detection and surveillance, and outlines a research and implementation roadmap to responsibly translate this paradigm into clinical oncology.
- 31 December 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (1) , 311
Open AccessThe Rise of Total-Body PET/CT: Advancing Molecular Imaging Toward Early Cancer Detection and Potential Future Application in Prevention Healthcare
Positron Emission Tomography (PET) is undergoing a profound transformation. Driven by the convergence of highly sensitive long-axial field-of-view (LAFOV) total-body PET systems and an expanding portfolio of targeted radiopharmaceuticals, PET is progressively evolving beyond its traditional role in oncologic diagnosis and staging. Ultra-sensitive scanners enable whole-body imaging with markedly reduced radiotracer doses, rapid acquisition times, and true dynamic multiparametric imaging across all organs simultaneously. In parallel, molecularly targeted radioligands support tumour phenotyping, theranostic applications, and personalized dosimetry. Together, these advances position PET as a systemic imaging platform capable of interrogating whole-body tumour biology, guiding precision therapies, and potentially enabling early detection or surveillance strategies in selected high-risk populations. This narrative review summarizes the technological foundations of total-body PET, reviews current clinical and translational applications, discusses opportunities and limitations for early detection and surveillance, and outlines a research and implementation roadmap to responsibly translate this paradigm into clinical oncology.